KALV
KalVista Pharmaceuticals Inc

3,105
Mkt Cap
$859.29M
Volume
1.38M
52W High
$19.00
52W Low
$9.24
PE Ratio
-4.25
KALV Fundamentals
Price
$17.00
Prev Close
$16.43
Open
$16.79
50D MA
$15.86
Beta
0.95
Avg. Volume
646,372.05
EPS (Annual)
-$3.69
P/B
50.55
Rev/Employee
$0.00
$575.29
Loading...
Loading...
News
all
press releases
Tudor Investment Corp ET AL Makes New $24.36 Million Investment in KalVista Pharmaceuticals, Inc. $KALV
Tudor Investment Corp ET AL acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership...
Business Wire·2d ago
News Placeholder
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Companys eight months fiscal year 2025 financial...
Business Wire·4d ago
News Placeholder
KalVista Pharmaceuticals (KALV) Projected to Post Quarterly Earnings on Tuesday
KalVista Pharmaceuticals (NASDAQ:KALV) will be releasing its Q4 2026 earnings before the market opens on Tuesday, March 24. (View Earnings Report at...
MarketBeat·5d ago
News Placeholder
Equities Analysts Issue Forecasts for KALV Q2 Earnings
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Research analysts at HC Wainwright raised their Q2 2026 EPS estimates for KalVista Pharmaceuticals in a report released on Thursday, March...
MarketBeat·6d ago
News Placeholder
Boxer Capital Management LLC Decreases Position in KalVista Pharmaceuticals, Inc. $KALV
Boxer Capital Management LLC lessened its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 78.2% during the third quarter, according to its most recent filing with the...
MarketBeat·7d ago
News Placeholder
What is HC Wainwright's Estimate for KALV FY2027 Earnings?
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at HC Wainwright boosted their FY2027 earnings estimates for shares of KalVista Pharmaceuticals in a research note...
MarketBeat·9d ago
News Placeholder
Benjamin Palleiko Sells 6,693 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 6,693 shares of the company's stock in a transaction on Monday, March 9th. The shares were sold at an average...
MarketBeat·11d ago
News Placeholder
Jefferies Financial Group Inc. Takes $3.49 Million Position in KalVista Pharmaceuticals, Inc. $KALV
Jefferies Financial Group Inc. purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the third quarter, according to its most recent filing with the...
MarketBeat·11d ago
News Placeholder
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 6,693 Shares of Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 6,693 shares of the company's stock in a transaction that occurred on Monday, March 9th. The shares were sold...
MarketBeat·12d ago
<
1
2
...
>

Latest KALV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.